These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35089113)

  • 41. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients.
    Kooistra EJ; van Berkel M; van Kempen NF; van Latum CRM; Bruse N; Frenzel T; van den Berg MJW; Schouten JA; Kox M; Pickkers P
    Crit Care; 2021 Aug; 25(1):281. PubMed ID: 34353339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
    Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G
    Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tocilizumab in critically ill COVID-19 patients: An observational study.
    Mushtaq MZ; Mahmood SBZ; Almas A; Ather Wasti S; Ahsan Ali S
    Int Immunopharmacol; 2022 Jan; 102():108384. PubMed ID: 34838490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
    Fernández-Ruiz M; López-Medrano F; Pérez-Jacoiste Asín MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM
    J Med Virol; 2021 Feb; 93(2):831-842. PubMed ID: 32672860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tocilizumab: A retrospective multi-center cohort study of critically ill patients with COVID-19.
    Villatoro Santos CR; Bhargava A; Coyle M; Szpunar S; Saravolatz LD
    Int J Clin Pharmacol Ther; 2021 Nov; 59(11):705-712. PubMed ID: 34448693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
    Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
    J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
    Van den Eynde E; Gasch O; Oliva JC; Prieto E; Calzado S; Gomila A; Machado ML; Falgueras L; Ortonobes S; Morón A; Capilla S; Navarro G; Oristrell J; Cervantes M; Navarro M
    Infect Dis (Lond); 2021 Apr; 53(4):291-302. PubMed ID: 33620019
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "Ventilator-free days" composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysis.
    Mady AF; Abdulrahman B; Mumtaz SA; Al-Odat MA; Kuhail A; Altoraifi R; Alshae R; Alharthy AM; Aletreby WT
    Heart Lung; 2022; 56():118-124. PubMed ID: 35839546
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.
    Knorr JP; Colomy V; Mauriello CM; Ha S
    J Med Virol; 2020 Nov; 92(11):2813-2820. PubMed ID: 32628003
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Experience with the use of siltuximab in patients with SARS-CoV-2 infection.
    Meira F; Albiach L; Carbonell C; Martín-Oterino JA; Martín-Ordiales M; Linares L; Macaya I; Agüero D; Ambrosioni J; Bodro M; Cardozo C; Chumbita M; De la Mora M; García-Pouton N; Garcia-Vidal C; González-Cordón A; Hernández-Meneses M; Inciarte A; Laguno M; Leal L; Morata L; Puerta-Alcalde P; Rico V; Letona L; Cózar-Llistó A; Dueñas G; Solá M; Torres B; Rojas J; Moreno A; Moreno-García E; Torres M; Martínez JA; Soriano A; García F
    Rev Esp Quimioter; 2021 Aug; 34(4):337-341. PubMed ID: 33982984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials.
    Klopfenstein T; Gendrin V; Kadiane-Oussou NJ; Conrozier T; Zayet S;
    Rev Med Virol; 2022 Jan; 32(1):e2239. PubMed ID: 33882179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis.
    Steuber TD; Rosandich T; Cadwallader T; Steil L; Belk M; Yendrapalli U; Hassoun A; Edwards J
    Ann Pharmacother; 2024 Apr; 58(4):391-397. PubMed ID: 37522616
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
    Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
    J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Primary observational study of tocilizumab in children with severe acute necrotizing encephalopathy].
    Zhou YP; Chen WM; Zhu XD; Jiang Q; Cui Y; Wang CX; Ren YQ; Lu GP; Zhang YC
    Zhonghua Er Ke Za Zhi; 2024 Aug; 62(8):764-769. PubMed ID: 39039879
    [No Abstract]   [Full Text] [Related]  

  • 56. Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.
    Singh AK; Oks M; Husk G; Dechario SP; Mina B; Singh K; Kirschenbaum L; Carpati CM; Mahmoud O; Gabra NI; Ishikawa O; Altschultz E; Shah V; Mahajan A; Gautam A; Birnbaum B; Antonacci AC; Raoof S
    Respir Care; 2021 Dec; 66(12):1805-1814. PubMed ID: 34548407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center.
    Martínez-Guerra BA; de-León-Cividanes NA; Tamez-Torres KM; Román-Montes CM; Rajme-López S; Ortiz-Brizuela E; Aguilar-Salinas CA; Sierra-Madero J; Sifuentes-Osornio J; Ponce-de-León A; González-Lara MF
    Rev Invest Clin; 2022 Jan; 74(1):40-50. PubMed ID: 34618802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of tocilizumab on intensive care patients with Covid-19 pneumonia, a retrospective cohort study.
    Küçük MP; Küçük AO; Pehlivanlar A; Mürtezaoğlu SA; Çoban K; Kılıç G; Ayçiçek O; Öztuna F; Bülbül Y; Özlü T
    Turk J Med Sci; 2022 Feb; 52(1):39-49. PubMed ID: 36161598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study.
    Aljuhani O; Al Sulaiman K; Alshabasy A; Eljaaly K; Al Shaya AI; Noureldeen H; Aboudeif M; Al Dosari B; Alkhalaf A; Korayem GB; Aleissa MM; Badreldin HA; Al Harbi S; Alhammad A; Vishwakarma R
    BMC Infect Dis; 2021 Nov; 21(1):1127. PubMed ID: 34724920
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
    Lohse A; Klopfenstein T; Balblanc JC; Royer PY; Bossert M; Gendrin V; Charpentier A; Bozgan AM; Badie J; Bourgoin C; Contreras R; Mazurier I; Conrozier T; Zayet S
    Microbes Infect; 2020 Oct; 22(9):500-503. PubMed ID: 32574789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.